COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort

Paul D. Jewell, Kate Bramham, James Galloway, Frank Post, Sam Norton, James Teo, Richard Fisher, Rohit Saha, Sam Hutchings, Phil Hopkins, Priscilla Smith, Jennifer Joslin, Satish Jayawardene, Sarah Mackie, Ali Mudhaffer, Amelia Holloway, Henry Kibble, Mosammat Akter, Benjamin Zuckerman, Kieran PalmerCiara Murphy, Domniki Iatropoulou, Claire C. Sharpe, Eirini Lioudaki

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)

Abstract

Background: Acute kidney injury (AKI) is common among patients hospitalised with COVID-19 and associated with worse prognosis. The aim of this study was to investigate the epidemiology, risk factors and outcomes of AKI in patients with COVID-19 in a large UK tertiary centre. Methods: We analysed data of consecutive adults admitted with a laboratory-confirmed diagnosis of COVID-19 across two sites of a hospital in London, UK, from 1st January to 13th May 2020. Results: Of the 1248 inpatients included, 487 (39%) experienced AKI (51% stage 1, 13% stage 2, and 36% stage 3). The weekly AKI incidence rate gradually increased to peak at week 5 (3.12 cases/100 patient-days), before reducing to its nadir (0.83 cases/100 patient-days) at the end the study period (week 10). Among AKI survivors, 84.0% had recovered renal function to pre-admission levels before discharge and none required on-going renal replacement therapy (RRT). Pre-existing renal impairment [odds ratio (OR) 3.05, 95%CI 2.24–4,18; p < 0.0001], and inpatient diuretic use (OR 1.79, 95%CI 1.27–2.53; p < 0.005) were independently associated with a higher risk for AKI. AKI was a strong predictor of 30-day mortality with an increasing risk across AKI stages [adjusted hazard ratio (HR) 1.59 (95%CI 1.19–2.13) for stage 1; p < 0.005, 2.71(95%CI 1.82–4.05); p < 0.001for stage 2 and 2.99 (95%CI 2.17–4.11); p < 0.001for stage 3]. One third of AKI3 survivors (30.7%), had newly established renal impairment at 3 to 6 months. Conclusions: This large UK cohort demonstrated a high AKI incidence and was associated with increased mortality even at stage 1. Inpatient diuretic use was linked to a higher AKI risk. One third of survivors with AKI3 exhibited newly established renal impairment already at 3–6 months.

Original languageEnglish
Article number359
Number of pages1
JournalBMC Nephrology
Volume22
Issue number1
Early online date1 Nov 2021
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • AKI
  • COVID-19
  • Mortality
  • Renal replacement therapy

Fingerprint

Dive into the research topics of 'COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort'. Together they form a unique fingerprint.

Cite this